| Age (y) | Median, 62 (range, 29-83) |
| Sex | |
| Male | 135 (61%) |
| Female | 83 (39%) |
| WBC × 103/μL | Median, 83 (range, 3-652) |
| Lymphocytes × 103/μL | 77 (6-340) |
| Platelets × 103/μL | 160 (12-541) |
| Hemoglobin g/dL | 12.5 (4-17.4) |
| β2M mg/L | 3.5 (1.3-15.4) |
| Bone marrow cellularity | 57 (10%-100%) |
| Bone marrow lymphocyte | 76 (20%-97.8%) |
| Rai | |
| 0-II | 160 (74%) |
| III-IV | 58 (26%) |
| Binet | |
| A + B | 163 (75%) |
| C | 55 (25%) |
| Lymph nodes involved | |
| 0-1 | 105 (48%) |
| 2-3 (or more) | 113 (52%) |
| No history of therapy | 142 (65%) |
| Positive history of therapy | 76 (36%) |
| Hepatomegaly | |
| No | 187 (86%) |
| Yes | 31 (14%) |
| Splenomegaly | |
| No | 161 (74%) |
| Yes | 57 (26%) |
| Age (y) | Median, 62 (range, 29-83) |
| Sex | |
| Male | 135 (61%) |
| Female | 83 (39%) |
| WBC × 103/μL | Median, 83 (range, 3-652) |
| Lymphocytes × 103/μL | 77 (6-340) |
| Platelets × 103/μL | 160 (12-541) |
| Hemoglobin g/dL | 12.5 (4-17.4) |
| β2M mg/L | 3.5 (1.3-15.4) |
| Bone marrow cellularity | 57 (10%-100%) |
| Bone marrow lymphocyte | 76 (20%-97.8%) |
| Rai | |
| 0-II | 160 (74%) |
| III-IV | 58 (26%) |
| Binet | |
| A + B | 163 (75%) |
| C | 55 (25%) |
| Lymph nodes involved | |
| 0-1 | 105 (48%) |
| 2-3 (or more) | 113 (52%) |
| No history of therapy | 142 (65%) |
| Positive history of therapy | 76 (36%) |
| Hepatomegaly | |
| No | 187 (86%) |
| Yes | 31 (14%) |
| Splenomegaly | |
| No | 161 (74%) |
| Yes | 57 (26%) |